Related MeSH Hierarchy (4)
Diseases [C] » Neoplasms [C04] » Neoplasms by Site » Hematologic Neoplasms » Bone Marrow Neoplasms » Polycythemia Vera
Diseases [C] » Hemic and Lymphatic Diseases [C15] » Hematologic Diseases » Bone Marrow Diseases » Bone Marrow Neoplasms » Polycythemia Vera
Diseases [C] » Hemic and Lymphatic Diseases [C15] » Hematologic Diseases » Bone Marrow Diseases » Myeloproliferative Disorders » Polycythemia Vera
Diseases [C] » Hemic and Lymphatic Diseases [C15] » Hematologic Diseases » Hematologic Neoplasms » Bone Marrow Neoplasms » Polycythemia Vera
Description
A myeloproliferative disorder of unknown etiology, characterized by abnormal proliferation of all hematopoietic bone marrow elements and an absolute increase in red cell mass and total blood volume, associated frequently with splenomegaly, leukocytosis, and thrombocythemia. Hematopoiesis is also reactive in extramedullary sites (liver and spleen). In time myelofibrosis occurs. MeSH
Hierarchy View
Approved Indicated Drugs (5)
Phase 2 Indicated Drugs (49)
Phase 1 Indicated Drugs (21)
Other Experimental Indicated Drugs (4)
Organization Involved with Phase 3 Indications (28)
Organization Involved with Phase 2 Indications (50)
Bankura Sammilani Medical College
Canadian Society of Hematology
Canadian Venous Thromboembolism Clinical Trials and Outcomes Research (CanVECTOR) Network
Organization Involved with Phase 1 Indications (18)
Organization Involved with Other Experimental Indications (1)
Hierarchy Tree View
UMLS Data
YOU AGREE THAT THE INFORMATION PROVIDED ON THIS WEBSITE IS PROVIDED “AS IS”, WITHOUT ANY WARRANTY OF ANY KIND, EXPRESSED OR IMPLIED, INCLUDING WITHOUT LIMITATION WARRANTIES OF MERCHANTABILITY OR FITNESS FOR ANY PARTICULAR PURPOSE, OR NON-INFRINGEMENT OF ANY THIRD-PARTY PATENT, COPYRIGHT, OR ANY OTHER THIRD-PARTY RIGHT. IN NO EVENT SHALL THE CREATORS OF THE WEBSITE OR WASHINGTON UNIVERSITY BE LIABLE FOR ANY DIRECT, INDIRECT, SPECIAL, OR CONSEQUENTIAL DAMAGES ARISING OUT OF OR IN ANY WAY CONNECTED WITH THE WEBSITE, THE USE OF THE WEBSITE, OR THIS AGREEMENT, WHETHER IN BREACH OF CONTRACT, TORT OR OTHERWISE, EVEN IF SUCH PARTY IS ADVISED OF THE POSSIBILITY OF SUCH DAMAGES.
